BiomX Inc.近期披露的交易方案显示,其并购对价组合包含可转换票据与认股权证。根据条款设计,两类金融工具的转换或行权价格均设定为每股12美元。这一结构既为交易提供了灵活性,也反映出交易双方对股价潜力的共识估值。
BiomX Inc.近期披露的交易方案显示,其并购对价组合包含可转换票据与认股权证。根据条款设计,两类金融工具的转换或行权价格均设定为每股12美元。这一结构既为交易提供了灵活性,也反映出交易双方对股价潜力的共识估值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.